menu
    • menu

    Company profile for Remedy Plan Therapeutics

    NEW Drugs in Dev: 1
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Remedy Plan Therapeutics is a privately-held, clinical-stage pharmaceutical company focused on transforming NAMPT inhibition. Their lead asset, RPT1G, is the first hyperbolic NAMPT inhibitor to be tested in humans, with broad therapeutic potential in cancer, autoimmune, and metabolic diseases. Remedy Plan initiated a Phase 1 clinical trial of RPT1G in adult healthy subjects in November 2024. The company aims to leverage this i...
    Remedy Plan Therapeutics is a privately-held, clinical-stage pharmaceutical company focused on transforming NAMPT inhibition. Their lead asset, RPT1G, is the first hyperbolic NAMPT inhibitor to be tested in humans, with broad therapeutic potential in cancer, autoimmune, and metabolic diseases. Remedy Plan initiated a Phase 1 clinical trial of RPT1G in adult healthy subjects in November 2024. The company aims to leverage this innovative approach to address a wide range of conditions with unmet medical needs, advancing the field of NAMPT inhibition.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Remedy Plan TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Gaithersburg, MD
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://remedyplan.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/remedy-plan/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Remedy Plan Therapeutics To Unveil Phase 1 NAMPT Inhibitor RPT1G
    Remedy Plan Therapeutics To Unveil Phase 1 NAMPT Inhibitor RPT1G

    04 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/04/3199720/0/en/Remedy-Plan-Therapeutics-to-Present-Results-from-Phase-1-Healthy-Volunteer-Study-of-NAMPT-Inhibitor-RPT1G-and-Other-Progress-at-the-67th-American-Society-of-Hematology-ASH-Annual-M.html

    GLOBENEWSWIRE
    04 Dec 2025
    Share Share
    Remedy Plan Therapeutics Progresses RPT1G For Myeloid Cancer
    Remedy Plan Therapeutics Progresses RPT1G For Myeloid Cancer

    12 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/12/3186175/0/en/Remedy-Plan-Therapeutics-Advances-RPT1G-for-Myeloid-Cancer-Patients-with-Phase-1-Safety-Data-and-IND-Approval.html

    GLOBENEWSWIRE
    12 Nov 2025
    Share Share
    Remedy Plan Raises $18M to Advance RPT1G into Phase 1/2 Trial
    Remedy Plan Raises $18M to Advance RPT1G into Phase 1/2 Trial

    13 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/13/3080034/0/en/Remedy-Plan-Therapeutics-Raises-18-Million-Financing-to-Accelerate-Advancement-of-Lead-Asset-RPT1G-into-Phase-1-2-Trials.html

    GLOBENEWSWIRE
    13 May 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search